Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 906-912

  Carlomagno, Chiara ^a   Farella, A ^b   Bucci, L ^b   D'Armiento, F P ^b   Pesce, G ^a   Pepe, S ^a   Cannella, L ^a   Pacelli, R ^b   De Stefano, A ^a   Solla, R ^b   D'Armiento, M R ^b   De Placido, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemoradiotherapy; Neo adjuvant; Rectal cancer

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DIARRHEA; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTITIS; RECTUM CANCER; STOMATITIS; TENESMUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 65549151863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn719     Document Type: Article

References (40)

1. Kamangar F, Dores GM, Anderson WF. Pattern of incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. GITSG. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312: 1465-1472.
3. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med 1991; 324: 709-715.
4. Tveit KM, Guldvog I, Hagen S et al. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Br J Surg 1997; 84: 1130-1135.
5. Cammà C, Giunta M, Fiorica F et al. Preoperative radiotherapy for respectable rectal cancer: A meta-analysis. JAMA 2000; 284: 1008-1015.
6. Colorectal Cancer Collaborative Group. Adjuvant therapy for rectal cancer: A systemic review of 22 randomized trials involved 8507 patients. Lancet 2001; 358: 1291-1304.
7. Peeters KCMY, Marijnen CAM, Nagtegaal ID et al. The TME trial after a median follow-up of 6 years. Increased local control but no survival benefit in irradiated patients with respectable rectal carcinoma. Ann Surg 2007; 246: 693-701.
8. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy, with or without concurrent 5fluorouracil and leucovorin in T3-T4 rectal cancers: Results of the FFCD 9203 trial. J Clin Oncol 2006; 24: 4620-4625.
9. Bosset JF, Colette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
10. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med 2004; 351: 1731-1740.
11. Bouzourene H, Bosman FT, Seelentag W et al. Importance of tumour regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 11212-21130.
12. Rödel C, Martus P, Papadopulos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
13. Chan AKP, Wong A, Jenken D et al. Post-treatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Rad Oncol Biol Phys 2005; 61: 665-676.
14. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: Analysis of phase II/III trials. Br J Radiol 2005; 78: 934-938.
15. Ben-Josef E. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. Am J Clin Oncol 2007; 30: 649-655.
16. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2967.
17. De Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow up of six years. J Clin Oncol 2007; 25 (18S Suppl): (Abstr 4007).
18. Kuebler JP, Wieand HS, O'Connel MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
19. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish cooperative group for treatment of digestive tumors trial. J Clin Oncol 2007; 25: 4224-4230.
20. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group. J Clin Oncol 2007; 25: 4217-4223.
21. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line treatment for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
22. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 2008; 26: 3523-3529.
23. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III trial. J Clin Oncol 2008; 26: 2013-2019.
24. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine-phosphorylase and enhances the efficacy of capecitabne (xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-2953.
25. Cividalli A, Ceciarelli F, Livdi E et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: Influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1098.
26. Rödel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
27. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 1994; 73: 2680-2686.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-13.
29. Vecchio FM, Valentini V, Minsky B et al. The relationship of pathological tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62: 752-760.
30. Theodoropoulos G, Wise WE, Padmanabhan A et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895-903.
31. Kuo LJ, Liu MC, Jian JJ et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 2007; 14: 2766-2772.
32. Capirci C, Velantini V, Cionini L et al. Prognostic value of complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
33. Machiels JP, Duck L, Honhon B et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: The RadiOxCape Study. Ann Oncol 2005; 16: 1898-1905.
34. Rödel C, Liersch T, Hermann RM et al. Multicenter phase II trial of chemotherapy with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25: 110-117.
35. Hospers GA, Punt CJ, Tesselaar ME et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007; 14: 2773-2779.
36. Fakih MG, Bullard Dun K, Yang GY et al. A phase II study of weekly intravenous oxaliplatin with oral daily capecitabine and radiotherapy with biological correlates in neoadjuvant treatment of rectal adenocarcinoma. Int J Rad Oncol Biol Phys 2008; 72: 650-657.
37. Rutten H, Sebag-Montefiore D, Glynne-Jones R et al. Capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006; 24 (Suppl): (Abstr 3528).
38. Alonso V, Lambea J, Salud A et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal carcinoma: A phase II trial. J Clin Oncol 2007; 25 (Suppl): (Abstr 4044).
39. Majem M, Navarro M, Losa F et al. Phase II clinical trial of weekly oxaliplatin with concurrent capecitabine plus preoperative radiotherapy in locally advanced respectable rectal cancer. J Clin Oncol 2008; 26 (Suppl): (Abstr 15013).
40. Marijnen CAM, Kapiteijn E, van de Velde CJH et al. Acute effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20: 817-825.